Journal
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 9, Issue 7, Pages 683-692Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/1744666X.2013.811046
Keywords
breastfeeding; corticosteroids; delivery; fingolimod; glatiramer acetate; IFN-beta; multiple sclerosis; natalizumab; postpartum; pregnancy
Categories
Ask authors/readers for more resources
As multiple sclerosis (MS) typically starts at about 30 years of age, and is twice more frequent in females than in males, women with MS frequently face issues related to pregnancy and to the effects of medications commonly used in MS treatment. In this review, the authors provide and summarize literature data addressing the effect of MS and its treatments on pregnancy, delivery, postpartum and conception. There is a strong evidence that relapses are fewer during pregnancy but more frequent during postpartum, and that IFN-beta and glatiramer acetate do not expose patients and their babies to relevant adverse events; nevertheless, these drugs should be discontinued during pregnancy and before conception. However, if their preventive withdrawal exposes patients to a high risk of disease activity, these medications could be continued until proven conception. Little information is available on the effect of natalizumab and fingolimod.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available